NO20073636L - Sammensetninger og metoder til a behandle mentale lidelser - Google Patents

Sammensetninger og metoder til a behandle mentale lidelser

Info

Publication number
NO20073636L
NO20073636L NO20073636A NO20073636A NO20073636L NO 20073636 L NO20073636 L NO 20073636L NO 20073636 A NO20073636 A NO 20073636A NO 20073636 A NO20073636 A NO 20073636A NO 20073636 L NO20073636 L NO 20073636L
Authority
NO
Norway
Prior art keywords
schizophrenia
bipolar disorder
disorders
compositions
methods
Prior art date
Application number
NO20073636A
Other languages
English (en)
Inventor
Ilya Chumakov
Daniel Cohen
Fabio Macciardi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20073636L publication Critical patent/NO20073636L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Den foreliggende oppfinnelse angår generelt fremgangsmåter og sammensetninger for å detektere eller behandle mentale lidelser, så som schizofreni eller bipolar hdelse. Den foreliggende oppflnnelse beskriver mer spesielt identiflkasjon av humane gener som kan anvendes for diagnose, forhindring og behandling av schizofreni, bipolar lidelse og beslektede lidelser, så vel som for screening av terapeutisk aktive medikamenter for å behandle nevnte lidelser. Oppflnnelsen beskriver videre spesiflkke polymorflsmer eller alleler av KCNQ3-genet som er relatert til schizofreni eller bipolar lidelse, så vel som diagnostiske verktøy og sett basert på disse markører. Oppflnnelsen kan anvendes til diagnose av eller disposisjon for, deteksjon, forhindring og/eller behandling av schizofreni, bipolar lidelse og beslektede lidelser.
NO20073636A 2004-12-24 2007-07-13 Sammensetninger og metoder til a behandle mentale lidelser NO20073636L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04293130 2004-12-24
PCT/EP2005/056660 WO2006067056A1 (en) 2004-12-24 2005-12-09 Compositions and methods for treating mental disorders

Publications (1)

Publication Number Publication Date
NO20073636L true NO20073636L (no) 2007-07-13

Family

ID=34931662

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073636A NO20073636L (no) 2004-12-24 2007-07-13 Sammensetninger og metoder til a behandle mentale lidelser

Country Status (8)

Country Link
US (1) US20070249518A1 (no)
EP (1) EP1828413A1 (no)
JP (1) JP2008524999A (no)
AU (1) AU2005318278A1 (no)
CA (1) CA2578071A1 (no)
IL (1) IL183931A0 (no)
NO (1) NO20073636L (no)
WO (1) WO2006067056A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075789A1 (en) * 2006-02-28 2008-03-27 The Regents Of The University Of California Genes differentially expressed in bipolar disorder and/or schizophrenia
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
DK2437744T3 (en) * 2009-06-03 2015-07-27 Univ Marquette The modulation of the KCNQ potassium channel activity for the treatment of psychiatric disorders and symptoms thereof
RU2588654C2 (ru) 2010-06-23 2016-07-10 Курна, Инк. Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna
DE102013108763A1 (de) 2013-08-13 2015-03-26 Krones Ag Vorrichtung und Verfahren zum Erwärmen von Kunststoffvorformlingen mit veränderter Teilung bei Vorformlingsübergabe
WO2020092577A1 (en) * 2018-10-30 2020-05-07 The Trustees Of Columbia University In The City Of New York Treatment of kcnq2 and kcnq3 gain of function-associated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175691A1 (en) * 1998-12-03 2004-09-09 Brown Barry S. Use of the KCNQ2 and KCNQ3 genes for the discovery of agents useful in the treatment of neurological disorders
AU2002318972B8 (en) * 2001-07-18 2007-08-09 Bionomics Limited Mutations in ion channels
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
WO2004047739A2 (en) * 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers

Also Published As

Publication number Publication date
EP1828413A1 (en) 2007-09-05
WO2006067056A1 (en) 2006-06-29
WO2006067056A9 (en) 2006-10-19
US20070249518A1 (en) 2007-10-25
JP2008524999A (ja) 2008-07-17
IL183931A0 (en) 2007-10-31
AU2005318278A1 (en) 2006-06-29
CA2578071A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
NO20073636L (no) Sammensetninger og metoder til a behandle mentale lidelser
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2008057691A3 (en) Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
WO2008052798A3 (en) Fgfr4 promotes cancer cell resistance in response to chemotherapeutic drugs
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
DK1766077T3 (da) Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
EP2270197A3 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
EP2540840A3 (en) Genetic variants on CHR16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
BRPI0512745A (pt) métodos de genotipagem e de caracterizar um agente e kit
DE60324925D1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
WO2008088861A3 (en) Gene polymorphisms predictive for dual tki therapy
WO2008143774A3 (en) Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
WO2008033461A3 (en) Methods for the identification, evaluation and treatment of patients having cc-chemokine receptor 2(ccr-2) mediated disorders
WO2004026107A3 (en) Kits and methods for assessing skin health
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
WO2006063703A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2007063405A3 (en) Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes using human cel gene
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
NO20050385L (no) Anvendelse av PP2A-fosfatasemodulatorer i behandlingen av mentale lidelser
WO2009140679A3 (en) Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application